About REXAHN

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing the next generation of targeted therapeutics for the treatment of cancer.
Rexahn's clinical development programs target specific proteins that are selectively localized in human cancer cells and not in healthy tissues resulting in increased efficacy and reduced toxicity.


News

Rexahn Presents Data from Preclinical Studies of RX-21101


Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting


More


Portfolio